{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T12:21:42Z","timestamp":1794399702756,"version":"4.9.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surveyophthalmol.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Survey of Ophthalmology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.survophthal.2026.06.001","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T08:08:48Z","timestamp":1780474128000},"page":"1591-1598","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Association of hydroxyurea use and sickle cell retinopathy: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"71","author":[{"given":"Faizan","family":"Naveed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7069-3162","authenticated-orcid":false,"given":"Brendan K.","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Ashamalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Mihalache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim S.","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marko M.","family":"Popovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kertes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaheer","family":"Aboobaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parnian","family":"Arjmand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian G.","family":"Ballios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3818-9788","authenticated-orcid":false,"given":"Peng","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.survophthal.2026.06.001_bib1","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1007\/s00417-019-04294-2","article-title":"Sickle cell retinopathy. A focused review","volume":"257","author":"Abdalla Elsayed","year":"2019","journal-title":"Graefe\u2019S Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.survophthal.2026.06.001_bib2","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/9131423","article-title":"The impact of optical coherence tomography in the early identification of children with sickle cell retinopathy","author":"Abdelkader","year":"2022","journal-title":"Int J Clin Pract"},{"issue":"13","key":"10.1016\/j.survophthal.2026.06.001_bib3","first-page":"573","article-title":"Hyperviscosity and hemolysis biomarkers in sickle cell ocular microangiopathy","volume":"55","author":"Agarwal","year":"2014","journal-title":"Invest Ophthalmol & Vis Sci"},{"issue":"4","key":"10.1016\/j.survophthal.2026.06.001_bib4","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence","volume":"64","author":"Balshem","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"13","key":"10.1016\/j.survophthal.2026.06.001_bib5","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1182\/bloodadvances.2022009147","article-title":"Natural history and rate of progression of retinopathy in adult patients with sickle cell disease: an 11-year follow-up study","volume":"7","author":"Brandsen","year":"2023","journal-title":"Blood Adv"},{"issue":"20","key":"10.1016\/j.survophthal.2026.06.001_bib6","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJM199505183322001","article-title":"Effect of hydroxyurea on the frequency of painful crises in Sickle cell anemia","volume":"332","author":"Charache","year":"1995","journal-title":"N ENGL J MED"},{"issue":"11","key":"10.1016\/j.survophthal.2026.06.001_bib7","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1002\/ajh.27439","article-title":"Advances in sickle cell retinopathy screening techniques, tests, and practices: A systematic review","volume":"99","author":"Cummings","year":"2024","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.survophthal.2026.06.001_bib8","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/ICU.0000000000000423","article-title":"Sickle cell disease and the eye","volume":"28","author":"Do","year":"2017","journal-title":"Curr Opin Ophthalmol"},{"issue":"11","key":"10.1016\/j.survophthal.2026.06.001_bib9","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/j.ophtha.2005.05.026","article-title":"Incidence and natural history of proliferative sickle cell retinopathy: Observations from a cohort study","volume":"112","author":"Downes","year":"2005","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.survophthal.2026.06.001_bib10","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s12288-014-0333-0","article-title":"Ocular Manifestations in Egyptian Children and Young Adults with Sickle Cell Disease","volume":"30","author":"El-Ghamrawy","year":"2014","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"21","key":"10.1016\/j.survophthal.2026.06.001_bib11","article-title":"The impact of hydroxyurea therapy on the prevalence of retinopathy in a pediatric sickle cell cohort","volume":"118","author":"Estepp","year":"2011","journal-title":"Blood [Internet]"},{"issue":"3","key":"10.1016\/j.survophthal.2026.06.001_bib12","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/bjh.12238","article-title":"Protection from sickle cell retinopathy is associated with elevated HbF levels and hydroxycarbamide use in children","volume":"161","author":"Estepp","year":"2013","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.survophthal.2026.06.001_bib13","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1136\/bjo.74.3.172","article-title":"Risk factors for proliferative sickle retinopathy","volume":"74","author":"Fox","year":"1990","journal-title":"BR J OPHTHALMOL"},{"issue":"7","key":"10.1016\/j.survophthal.2026.06.001_bib14","first-page":"205","article-title":"Effect of hydroxyurea in preventing ocular complications in Sickle Cell Disease (Italian Study)","volume":"56","author":"Gagliano","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"8","key":"10.1016\/j.survophthal.2026.06.001_bib15","article-title":"Sickle cell retinopathy: Is there a role for follow-up?","volume":"62","author":"Gallo","year":"2021","journal-title":"Invest Ophthalmol Vis Sci [Internet]"},{"key":"10.1016\/j.survophthal.2026.06.001_bib16","unstructured":"Higgins J.T.J.C.J. eds, et al. Cochrane Handbook for Systematic Reviews of Interventions. Version 6.5. ."},{"issue":"2","key":"10.1016\/j.survophthal.2026.06.001_bib17","first-page":"MR000010","article-title":"Grey literature in meta-analyses of randomized trials of health care interventions","author":"Hopewell","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.survophthal.2026.06.001_bib18","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1001\/jama.2022.10233","article-title":"Sickle cell disease: a review","volume":"328","author":"Kavanagh","year":"2022","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.survophthal.2026.06.001_bib19","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.ophtha.2019.02.023","article-title":"Prevalence and onset of pediatric sickle cell retinopathy","volume":"126","author":"Li","year":"2019","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.survophthal.2026.06.001_bib20","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1001\/jamaophthalmol.2020.6525","article-title":"Longitudinal assessment of retinal thinning in adults with and without sickle cell retinopathy using spectral-domain optical coherence tomography","volume":"139","author":"Lim","year":"2021","journal-title":"JAMA Ophthalmol"},{"issue":"5","key":"10.1016\/j.survophthal.2026.06.001_bib21","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/bjh.15617","article-title":"Elevated fetal haemoglobin levels are associated with decreased incidence of retinopathy in adults with sickle cell disease","volume":"183","author":"Mian","year":"2018","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.survophthal.2026.06.001_bib22","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s40942-022-00419-8","article-title":"Risk factors associated with sickle cell retinopathy: findings from the cooperative study of sickle cell disease","volume":"8","author":"Nawaiseh","year":"2022","journal-title":"Int J Retin Vitr"},{"issue":"9","key":"10.1016\/j.survophthal.2026.06.001_bib23","first-page":"958","article-title":"Vitreous hemorrhage, aetiology and visual outcome of vitrectomy in a Black African population","volume":"39","author":"Okonkwo","year":"2022","journal-title":"West Afr J Med"},{"issue":"5","key":"10.1016\/j.survophthal.2026.06.001_bib24","first-page":"1061","article-title":"The modern use of hydroxyurea for children with sickle cell anemia","volume":"110","author":"Quinn","year":"2025","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.survophthal.2026.06.001_bib25","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.bjhh.2016.09.007","article-title":"Clinical and laboratory profile of patients with sickle cell anemia","volume":"39","author":"Sant\u2019Ana","year":"2017","journal-title":"Rev Bras Hematol Hemoter"},{"issue":"6","key":"10.1016\/j.survophthal.2026.06.001_bib26","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1111\/bjh.19832","article-title":"Baseline characteristics of Ghanaian children and adults enrolled in PIVOT, a randomised clinical trial of hydroxyurea in HbSC disease in sub-Saharan Africa","volume":"205","author":"Segbefia","year":"2024","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.survophthal.2026.06.001_bib27","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1080\/02713683.2023.2242010","article-title":"Identifying clinical predictors of proliferative sickle cell retinopathy","volume":"48","author":"Serras-Pereira","year":"2023","journal-title":"Curr Eye Res"},{"issue":"8","key":"10.1016\/j.survophthal.2026.06.001_bib28","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.ophtha.2025.03.031","article-title":"Investigation of sickle cell retinopathy in pediatric and adolescent patients enrolled in a large cohort study","volume":"132","author":"Smith","year":"2025","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.survophthal.2026.06.001_bib29","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/trstmh\/trt008","article-title":"Retinal changes in children and adolescents with sickle cell disease attending a paediatric hospital in cairo, egypt: Risk factors and relation to ophthalmic and cerebral blood flow","volume":"107","author":"Tantawy","year":"2013","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"9","key":"10.1016\/j.survophthal.2026.06.001_bib30","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.oret.2025.03.001","article-title":"Risk and dose-response relationship for pentosan polysulfate sodium maculopathy: a systematic review and meta-analysis","volume":"9","author":"Tao","year":"2025","journal-title":"Ophthalmol Retin"},{"issue":"4","key":"10.1016\/j.survophthal.2026.06.001_bib31","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s40123-024-00893-3","article-title":"Proliferative sickle cell retinopathy: a patient and a physician\u2019s perspective on quality of life and quality of eye care","volume":"13","author":"Taylor","year":"2024","journal-title":"Ophthalmol Ther"},{"issue":"1","key":"10.1016\/j.survophthal.2026.06.001_bib32","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/pbc.22822","article-title":"Clinical complications in severe pediatric sickle cell disease and the impact of hydroxyurea","volume":"56","author":"Tripathi","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.survophthal.2026.06.001_fur1","doi-asserted-by":"crossref","unstructured":"Estepp J.H., Smeltzer M.P., Wang W.C., et al. Protection from sickle cell retinopathy is associated with elevated HbF levels and hydroxycarbamide use in children. Br J Haematol. 2013;161(3):402\u2013405. This study was included for its explicit reporting of hydroxyurea use and sickle cell retinopathy outcomes, allowing for direct comparisons between exposure groups.","DOI":"10.1111\/bjh.12238"},{"key":"10.1016\/j.survophthal.2026.06.001_fur2","doi-asserted-by":"crossref","unstructured":"Li J., Bender L., Shaffer J., et al. Prevalence and Onset of Pediatric Sickle Cell Retinopathy. Ophthalmology. 2019;126(7):1000\u20131006. This study was included for its explicit reporting of hydroxyurea use and sickle cell retinopathy outcomes, allowing for direct comparisons between exposure groups.","DOI":"10.1016\/j.ophtha.2019.02.023"},{"key":"10.1016\/j.survophthal.2026.06.001_fur3","doi-asserted-by":"crossref","unstructured":"Mian U.K., Tang J., Allende A.P.M., et al. Elevated fetal haemoglobin levels are associated with decreased incidence of retinopathy in adults with sickle cell disease. Br J Haematol. 2018;183(5):807 EP \u2013 811. doi:10.1111\/bjh.15617. This study was included for its explicit reporting of hydroxyurea use and sickle cell retinopathy outcomes, allowing for direct comparisons between exposure groups.","DOI":"10.1111\/bjh.15617"},{"key":"10.1016\/j.survophthal.2026.06.001_fur4","doi-asserted-by":"crossref","unstructured":"Smith B.D., Hankins J.S., Kang G., et al. Investigation of Sickle Cell Retinopathy in Pediatric and Adolescent Patients Enrolled in a Large Cohort Study. Ophthalmology. 2025;132(8):911\u2013920. This study was included for its explicit reporting of hydroxyurea use and sickle cell retinopathy outcomes, allowing for direct comparisons between exposure groups.","DOI":"10.1016\/j.ophtha.2025.03.031"},{"key":"10.1016\/j.survophthal.2026.06.001_fur5","doi-asserted-by":"crossref","unstructured":"Tripathi A., Jerrell J.M., Stallworth J.R. Clinical complications in severe pediatric sickle cell disease and the impact of hydroxyurea. Pediatr Blood Cancer. 2011;56(1):90\u201394. This study was included for its explicit reporting of hydroxyurea use and sickle cell retinopathy outcomes, allowing for direct comparisons between exposure groups.","DOI":"10.1002\/pbc.22822"}],"container-title":["Survey of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625726000767?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625726000767?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:21:18Z","timestamp":1788949278000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039625726000767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0039625726000767"],"URL":"https:\/\/doi.org\/10.1016\/j.survophthal.2026.06.001","relation":{},"ISSN":["0039-6257"],"issn-type":[{"value":"0039-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of hydroxyurea use and sickle cell retinopathy: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Survey of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.survophthal.2026.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}